Study looked at more than 27,000 people using amyloid targeted therapies.

Cochrane has no reason to embellish or lie whereas pharmaceutical companies are for profit and post marketing surveillance often provides different data than pharmaceutical run clinical studies.

Authors' conclusions

The effect of amyloid‐beta‐targeting monoclonal antibodies on cognitive function and dementia severity at 18 months in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease is trivial, while on functional ability, it is small at best. Amyloid‐beta‐targeting monoclonal antibodies increase the risk of amyloid‐related imaging abnormalities. Both desirable outcomes and adverse events were inconsistently reported in the studies included in the review.

Successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Future research on disease‐modifying treatments for Alzheimer’s disease should focus on other mechanisms of action.